ID   QBC939/ADM
AC   CVCL_LJ49
DR   Wikidata; Q54948795
RX   PubMed=20111907;
CC   Population: Chinese.
CC   Doubling time: 32.2 hours (PubMed=20111907).
CC   Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
DI   NCIt; C4436; Cholangiocarcinoma
DI   ORDO; Orphanet_70567; Cholangiocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_6942 ! QBC939
SX   Male
AG   51Y
CA   Cancer cell line
DT   Created: 15-11-17; Last updated: 21-03-23; Version: 6
//
RX   PubMed=20111907; DOI=10.1007/s11033-010-9975-7;
RA   Liu Z.-H., He Y.-P., Zhou Y.-K., Zhang P., Qin H.-L.;
RT   "Establishment and identification of the human multi-drug-resistant
RT   cholangiocarcinoma cell line QBC939/ADM.";
RL   Mol. Biol. Rep. 38:3075-3082(2011).
//